{
    "clinical_study": {
        "@rank": "146469", 
        "arm_group": [
            {
                "arm_group_label": "loading dose of colistin", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous"
            }, 
            {
                "arm_group_label": "without loading dose of colistin", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive 3 million international units of colistin every 8 hours intravenous"
            }
        ], 
        "brief_summary": {
            "textblock": "The study hypothesis is that  the loading dose of intravenous colistin (6 million of\n      international units) is associated with greater clinical and microbiological efficacy, and\n      reduced mortality of critically ill patients infected by multidrug resistant Gram- negative\n      bacilli, compared to a scheme without loading dose."
        }, 
        "brief_title": "Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gram Negative Bacterial Infections", 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Gram-Negative Bacterial Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is a prospective, multicenter, randomized, controlled study to evaluate a scheme with and\n      without a loading dose of 6 million international units of colistin, followed by a\n      maintenance dose of 3 million international units every 8 hours intravenous. The study\n      should be conducted in 3 hospitals in Chile, in critically patients presenting infection by\n      multidrug Gram-negative bacteria and requiring be treated with colistin for at least 48\n      hours. The objectives of the study are: to evaluate the clinical and microbiological\n      response, and mortality."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient hospitalized in critical care units\n\n          -  patient infected by multi drug resistant Gram negative bacteria susceptibly only to\n             colistin\n\n          -  source of infection: blood, respiratory or urinary\n\n        Exclusion Criteria:\n\n          -  pregnant or breastfeeding patients\n\n          -  patients in hemodialysis prior to be admitted to the study\n\n          -  patient with a history of hypersensitivity to colistin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117986", 
            "org_study_id": "SA13I20317"
        }, 
        "intervention": {
            "arm_group_label": [
                "loading dose of colistin", 
                "without loading dose of colistin"
            ], 
            "description": "One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.", 
            "intervention_name": "colistin", 
            "intervention_type": "Drug", 
            "other_name": [
                "colistimethate sodium", 
                "polymyxin e"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Colistin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "critically ill patients", 
            "colistin dosing", 
            "multidrug resistant bacteria"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rojasloreto@gmail.com", 
                    "last_name": "Loreto Rojas, MD, PhD", 
                    "phone": "56-9-68479281"
                }, 
                "contact_backup": {
                    "email": "ruth.rosales@vtr.net", 
                    "last_name": "Ruth Rosales, PharmD", 
                    "phone": "56-9-95093184"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile", 
                        "state": "Metropolitana"
                    }, 
                    "name": "Hospital El Pino"
                }, 
                "investigator": [
                    {
                        "last_name": "Arie Altman, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Julia Gil, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rojasloreto@gmail.com", 
                    "last_name": "Loreto Rojas, MD", 
                    "phone": "56-9-68479281"
                }, 
                "contact_backup": {
                    "email": "ruth.rosales@vtr.net", 
                    "last_name": "Ruth Rosales, PharmD", 
                    "phone": "56-9-9093184"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile", 
                        "state": "Region Metropolitana", 
                        "zip": "8900085"
                    }, 
                    "name": "Hospital Barros Luco Trudeau"
                }, 
                "investigator": [
                    {
                        "last_name": "Ruth Rosales, PharmD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Alexis Castro, PharmD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ronald Pauramani, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Loreto Rojas, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jorge Silva, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sheyla Jimenez, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sof\u00eda Palma, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Carlos Beltr\u00e1n, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Chile"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients", 
        "overall_contact": {
            "email": "rojasloreto@gmail.com", 
            "last_name": "Loreto Rojas, MD", 
            "phone": "56-9-68479281"
        }, 
        "overall_contact_backup": {
            "email": "ruth.rosales@vtr.net", 
            "last_name": "Ruth Rosales, PharmD", 
            "phone": "56-9-95093184"
        }, 
        "overall_official": {
            "affiliation": "Hospital Barros Luco Trudeau", 
            "last_name": "Loreto Rojas, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Chile: Comit\u00e9 de \u00c9tica Cient\u00edfico", 
                "Chile: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "remission or reduction of clinical signs of infection", 
                "measure": "Percentage of patients with clinical response to treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 1 week"
            }, 
            {
                "description": "negative culture at the same site where the positive culture was obtained before", 
                "measure": "percentage of patients with microbiological response", 
                "safety_issue": "No", 
                "time_frame": "up to 1 week"
            }, 
            {
                "description": "the mortality during their stay in the intensive care unit, an expected average of 4 weeks", 
                "measure": "mortality", 
                "safety_issue": "No", 
                "time_frame": "during their stay in the intensive care unit"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hospital Barros Luco Trudeau", 
        "sponsors": {
            "collaborator": {
                "agency": "Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico, Chile", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hospital Barros Luco Trudeau", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}